Related Experiment Video
Updated: May 22, 2026
09:11
Alternating Magnetic Field-Responsive Hybrid Gelatin Microgels for Controlled Drug Release
Published on: February 13, 2016
Formulation and evaluation of olanzapine matrix pellets for controlled release
N Vishal Gupta1, Dv Gowda, V Balamuralidhara
1Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Sri Shivarathreeshwara Nagar, Mysore-570015, Karnataka, India.
Summary
Oral controlled-release pellets of olanzapine (OZ) were successfully designed using sodium alginate and glyceryl palmito-stearate. The optimized formulation (F5) demonstrated stable characteristics and sustained drug release for over 24 hours, ideal for once-daily administration.
Area of Science:
- Pharmaceutical Technology
- Drug Delivery Systems
- Materials Science
Background:
- Olanzapine (OZ) is an antipsychotic medication used for schizophrenia.
- Water-insoluble drugs present challenges for oral controlled-release formulations.
- Developing effective delivery systems is crucial for improving therapeutic outcomes.
Purpose of the Study:
- To design and characterize oral controlled-release matrix pellets of olanzapine (OZ).
- To utilize a blend of Sodium Alginate (SA) and Glyceryl Palmito-Stearate (GPS) as matrix polymers.
- To incorporate Microcrystalline Cellulose (MCC) as a spheronizer enhancer and Sodium Lauryl Sulphate (SLS) as a pore-forming agent.
Main Methods:
- Pelletization technique was employed for formulating drug-loaded pellets.
- Characterization included drug content, particle size distribution, SEM, DSC, FTIR, and XRD.
- Stability studies were conducted on the optimized formulation over 90 days under accelerated conditions.
Main Results:
- Drug content ranged from 93.34-98.12% with mean particle size between 1024-1087µm.
- SEM confirmed spherical pellet morphology; DSC and FTIR indicated drug-polymer compatibility.
- Stability studies confirmed the integrity of the pellets; XRD showed crystalline OZ presence.
Conclusions:
- The optimized formulation (F5) exhibited controlled drug release for over 24 hours via Fickian diffusion.
- Formulation F5 demonstrated excellent stability and drug content.
- The designed pellets are suitable for once-daily olanzapine administration.
Related Concept Videos
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:23Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...